-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Trade Alert: The Founder Of Clover Biopharmaceuticals, Ltd. (HKG:2197), Peng Liang, Has Just Spent CN¥1.0m Buying A Few More Shares
Trade Alert: The Founder Of Clover Biopharmaceuticals, Ltd. (HKG:2197), Peng Liang, Has Just Spent CN¥1.0m Buying A Few More Shares
Potential Clover Biopharmaceuticals, Ltd. (HKG:2197) shareholders may wish to note that the Founder, Peng Liang, recently bought HK$1.0m worth of stock, paying HK$3.63 for each share. Although the purchase is not a big one, by either a percentage standpoint or absolute value, it can be seen as a good sign.
See our latest analysis for Clover Biopharmaceuticals
The Last 12 Months Of Insider Transactions At Clover Biopharmaceuticals
Notably, that recent purchase by Founder Peng Liang was not the only time they bought Clover Biopharmaceuticals shares this year. Earlier in the year, they paid HK$1.92 per share in a HK$1.2m purchase. Although we like to see insider buying, we note that this large purchase was at significantly below the recent price of HK$2.86. While it does suggest insiders consider the stock undervalued at lower prices, this transaction doesn't tell us much about what they think of current prices.
Peng Liang purchased 1.80m shares over the year. The average price per share was HK$2.12. You can see a visual depiction of insider transactions (by companies and individuals) over the last 12 months, below. If you want to know exactly who sold, for how much, and when, simply click on the graph below!
SEHK:2197 Insider Trading Volume December 21st 2022Clover Biopharmaceuticals is not the only stock that insiders are buying. For those who like to find winning investments this free list of growing companies with recent insider purchasing, could be just the ticket.
Insider Ownership Of Clover Biopharmaceuticals
I like to look at how many shares insiders own in a company, to help inform my view of how aligned they are with insiders. I reckon it's a good sign if insiders own a significant number of shares in the company. Insiders own 20% of Clover Biopharmaceuticals shares, worth about HK$733m. We've certainly seen higher levels of insider ownership elsewhere, but these holdings are enough to suggest alignment between insiders and the other shareholders.
So What Do The Clover Biopharmaceuticals Insider Transactions Indicate?
The recent insider purchase is heartening. And the longer term insider transactions also give us confidence. But on the other hand, the company made a loss during the last year, which makes us a little cautious. When combined with notable insider ownership, these factors suggest Clover Biopharmaceuticals insiders are well aligned, and quite possibly think the share price is too low. That's what I like to see! While we like knowing what's going on with the insider's ownership and transactions, we make sure to also consider what risks are facing a stock before making any investment decision. To help with this, we've discovered 3 warning signs (2 are concerning!) that you ought to be aware of before buying any shares in Clover Biopharmaceuticals.
If you would prefer to check out another company -- one with potentially superior financials -- then do not miss this free list of interesting companies, that have HIGH return on equity and low debt.
For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions, but not derivative transactions.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
潜力 三叶草生物制药有限公司 (HKG: 2197) 股东不妨注意,创始人彭亮最近购买了价值100万港元的股票,每股支付了3.63港元。尽管从百分比或绝对价值的角度来看,此次收购并不是一件大事,但可以将其视为一个好兆头。
查看我们对三叶草生物制药的最新分析
三叶草生物制药最近12个月的内幕交易
值得注意的是,创始人彭亮最近的收购并不是他们今年唯一一次购买三叶草生物制药的股票。今年早些时候,他们在120万港元的收购中每股支付了1.92港元。尽管我们希望看到内幕买盘,但我们注意到这次大规模收购的价格大大低于最近的2.86港元。尽管这确实表明内部人士认为该股在较低的价格下被低估了,但这笔交易并没有告诉我们太多他们对当前价格的看法。
彭亮在年内购买了180万股股票。每股平均价格为2.12港元。您可以在下面看到对过去 12 个月内幕交易(公司和个人)的直观描述。如果你想确切地知道谁卖了,卖了多少钱,什么时候卖了,只需点击下面的图表即可!
SEHK: 2197 2022 年 12 月 21 日内幕交易量Clover Biopharmaceuticals并不是内部人士唯一买入的股票。对于那些喜欢寻找的人 获胜的投资 这个 免费的 最近进行内幕收购的成长型公司名单可能只是门票。
三叶草生物制药的内部所有权
我喜欢看看内部人士在一家公司拥有多少股票,以帮助我了解他们与内部人士的共识程度。我认为,如果内部人士拥有该公司的大量股份,这是一个好兆头。业内人士拥有三叶草生物制药20%的股份,价值约7.33亿港元。当然,我们在其他地方看到了更高的内部所有权水平,但这些持股足以表明内部人士与其他股东保持一致。
那么,三叶草生物制药的内幕交易表明了什么呢?
最近的内幕收购令人振奋。长期的内幕交易也给了我们信心。但另一方面,该公司在去年出现了亏损,这使我们有点谨慎。再加上显著的内部所有权,这些因素表明Clover Biopharmaceuticals的内部人士非常一致,很可能认为股价太低了。这就是我喜欢看到的!虽然我们喜欢知道内部人士的所有权和交易发生了什么,但在做出任何投资决定之前,我们也一定要考虑股票面临的风险。为了帮助解决这个问题,我们发现 3 个警告标志 (2 个令人担忧!)在购买Clover Biopharmaceuticals的任何股票之前,你应该注意这一点。
如果你想去另一家公司看看 —— 一家财务状况可能优异的公司 —— 那千万不要错过这个 免费的 股本回报率高、债务低的有趣公司名单。
就本文而言,内部人士是指向相关监管机构报告交易的个人。我们目前用于公开市场交易和私人处置,但不包括衍生品交易。
对这篇文章有反馈吗?对内容感到担忧? 取得联系 直接和我们联系。 或者,给编辑团队 (at) simplywallst.com 发送电子邮件。
Simply Wall St 的这篇文章本质上是一般性的。 我们仅使用不偏不倚的方法根据历史数据和分析师预测提供评论,我们的文章并非旨在提供财务建议。 它不构成买入或卖出任何股票的建议,也没有考虑您的目标或财务状况。我们的目标是为您提供由基本面数据驱动的长期重点分析。请注意,我们的分析可能未将最新的价格敏感型公司公告或定性材料考虑在内。简而言之,华尔街对上述任何股票都没有头寸。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧